JAZZ Stock — Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals PLC (JAZZ)

Updated October 16, 2026.

JAZZ is a Stock. Total return is 1085.7% over the past 19.4 years, 478.4 points ahead of SPY at 607.3%.

Jazz Pharmaceuticals plc is a pharmaceutical company that identifies, develops, and commercializes drugs for conditions including narcolepsy, epilepsy, certain cancers, and other rare diseases, with marketed products like Xywav, Epidiolex, and Zepzelca, and a pipeline of treatments in clinical trials. The company does not currently have an established distribution schedule. Jazz Pharmaceuticals operates internationally with headquarters in Dublin, Ireland, and appeals primarily to investors seeking exposure to specialty pharmaceuticals and rare disease treatments rather than current income.

JAZZ performance versus SPY

Price and return data through 2026-10-16.

Total return is 1085.7% over the past 19.4 years, 478.4 points ahead of SPY at 607.3%. Over the past year its total return — price change plus distributions reinvested — is 56.6%. Its deepest 1-year drawdown was 19.9%.

JAZZ key facts

Asset type

Stock

Asset class

Equity

Inception date

06/01/2007

Distribution frequency

None

Last close

$210.23 (as of 2026-10-16)

Market cap

$13,646,991,523

Average volume

636693.0

Beta

0.369

Payout ratio

0.0%

P/E ratio

14.46

Forward P/E

10.8932

EPS

$14.54

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

JAZZ risks and drawbacks

The deepest 1-year drawdown on record here is 19.9%.

Who may consider JAZZ — and who may not

It is a weaker fit for investors who need monthly cash flow (JAZZ does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on JAZZ

• All tickers starting with J

Tagged: Healthcare.

Frequently asked questions